



Affymetrix Tumor Profiling Grant Program

Apply a multi-omics approach to biomarker discovery

How do you derive clinically relevant biomarkers?

Systematic tumor profiling with multi-omics tools and rapid analytical validation is a powerful way to discover clinically relevant biomarkers and increase the probability of success.

The parallel analysis of any combination of SNP, copy number variation, gene expression and regulation, protein expression, or cellular analysis enables rapid identification of the most robust biomarkers for impactful clinical application. The data from one type of analyte can provide biological validation for another, enhancing the diagnostic power and increasing confidence in the final biomarkers selected towards routine clinical use.

Affymetrix wants to help.

Affymetrix Tumor Profiling Grant Program aims to support translational cancer researchers who are discovering and analytically validating biomarkers that can eventually be used to address unmet clinical needs in cancer treatment.

Affymetrix will award up to three researchers resident in the European Union ("EU") or Norway, Switzerland, Bahrain, Israel, Jordan, Kuwait, Morocco, Oman, Qatar, Russia, Saudi Arabia, South Africa, Tunisia, Turkey or United Arab Emirates with the tools to measure and validate at least two different analytes—DNA, RNA, proteins, or cells—in 30 tumor samples.

Grant program application criteria.

To qualify for Affymetrix Tumor Profiling Grant Program, you must

- Seek biomarkers that address a significant unmet clinical need.
- Have a plan to validate towards a routine test after the discovery and analytical study.
- Combine the analysis of at least two different molecular or cellular parameters from the following: copy number variation, SNPs, gene or transcript isoform expression, long and small non-coding RNA expression, cytokines, cell surface markers, soluble proteins.
- Have 30 samples (FFPE, fresh frozen tissue, or blood) collected and ready for processing.
- Profile the samples using the most appropriate Affymetrix technology according to manufacturer's guidelines.
- Generate and interpret preliminary results no later than 31st August 2016, with final data completed no later than 30th December 2016.
- Be willing and able to present data at an Affymetrix-sponsored event no later than 31st May 2017.

Apply today.

www.surveymonkey.com/r/AffyTumorGrant_EMEA
#AffyTumorGrant

Let Affymetrix sponsor your tumor profiling project to discover and validate the best biomarker.

Affymetrix provides proven solutions for the identification and validation of DNA, RNA, protein, and cellular biomarkers in your clinical samples. Choose the best technology for your selected analytes from the table below, and include your choices in the grant application.

Analyte	Biomarker identification	Analytical validation
DNA Genotyping Copy number	<ul style="list-style-type: none"> Human SNP analysis Axiom® Genotyping Solution Copy number variation in blood CytoScan® Cytogenetics Suite Copy number variation in FFPE tissue OncoScan® FFPE Assay Kit 	<ul style="list-style-type: none"> Single targets QuantiGene® Singleplex DNA Assays Single- to low-plex targets VeriQuest® qPCR master mix reagents <33 targets QuantiGene® Plex DNA Assays
RNA Gene expression Gene regulation	<ul style="list-style-type: none"> Whole-transcriptome analysis GeneChip® Human Transcriptome Array (HTA) 2.0 <i>and</i> Flexible sample preparation GeneChip® WT Pico Kit Small non-coding RNA analysis GeneChip® miRNA 4.0 Array 	<ul style="list-style-type: none"> Single targets QuantiGene® Singleplex Assays Single- to low-plex targets VeriQuest® qPCR master mix reagents <80 targets QuantiGene® Plex Assays Visualization of 1–4 targets per cell ViewRNA® Assays Gene expression in isolated cells PrimeFlow™ RNA Assays Single targets QuantiGene® miRNA Assays
Protein and cells Multiplex cytokine profiling Flow cytometry Immunophenotyping	<ul style="list-style-type: none"> Multiplex immunoassays ProcartaPlex™ Multiplex Immunoassays 	<ul style="list-style-type: none"> Protein titer determination Platinum, Instant®, InstantOne™, High Sensitivity, and Ready-SET-Go!® ELISAs Immunophenotyping in cell suspensions Flow cytometry reagents Immunohistochemistry (IHC) and immunocytochemistry (ICC) Antibodies for IHC and ICC

Apply today.

www.surveymonkey.com/r/AffyTumorGrant_EMEA
#AffyTumorGrant

Grant program terms and conditions

Affymetrix Tumor Profiling Grant Program will award three researchers/research groups or consortia from the EU or Norway, Switzerland, Bahrain, Israel, Jordan, Kuwait, Morocco, Oman, Qatar, Russia, Saudi Arabia, South Africa, Tunisia, Turkey or United Arab Emirates with the consumables required to analyze two different analytes (RNA, DNA, proteins, or cells) in 30 tumor samples, stored as either fresh frozen, formalin-fixed paraffin-embedded, or blood tissue. Applications must be received via SurveyMonkey by 8 PM GMT on 31st December 2015. All samples must be processed and analyzed by 30th December 2016. Winners will be selected based on scientific and clinical merit and compliance with the grant program criteria: (1) Applicants must have 30 samples (FFPE, fresh frozen tissue, or blood) already collected and ready for processing; (2) All samples must have received ethical consent to be used for research purposes; (3) Winners must be prepared to analyze at least two different molecular or cellular parameters that can be addressed by Affymetrix® products; (4) All products must be used in accordance with manufacturer's guidelines; (5) All data generated by the study is owned by the winner. Winners must be willing to share the data with Affymetrix and grant permission to Affymetrix to use the data for commercial and/or training purposes, anonymously if required; (6) Winners must be willing and able to present preliminary results from the study internally to Affymetrix on or before 31st August 2016; (7) Winners must be willing and able to present the results during at least one Affymetrix sponsored event, which may include but not be limited to scientific conferences, workshops, webinars, seminars, interviews, no later than 31st May 2017. Winners will be announced on 29th January 2016. No purchase necessary. Void where prohibited. Open to residents of the EU or Norway, Switzerland, Bahrain, Israel, Jordan, Kuwait, Morocco, Oman, Qatar, Russia, Saudi Arabia, South Africa, Tunisia, Turkey or United Arab Emirates.

For Research Use Only. Not for use in diagnostic procedures.

©2015 Affymetrix, Inc. All rights reserved. All other trademarks are the property of their respective owners